Mitochondrial neurogastrointestinal encephalomyopathy

MONDO:0017575

A syndrome characterized by the association of gastrointestinal dysmotility, peripheral neuropathy, chronic progressive external ophthalmoplegia and leukoencephalopathy.

Also known as: MNGIE, Mitochondrial Neurogastrointestinal Encephalopathy, Mitochondrial neurogastrointestinal encephalopathy, mitochondrial Neurogastrointestingal encephalopathy, MNGIE syndrome, OGIMD, POLIP, mitochondrial neurogastrointestinal encephalopathy syndrome

26 clinical trials for this condition and its sub-types, 4 tagged with Mitochondrial neurogastrointestinal encephalomyopathy itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Syndromic disease (7133) ↑ Hereditary peripheral neuropathy (478) ↑ Congenital nervous system disorder (284) ↑ Inborn mitochondrial myopathy (45) ↑ Inborn disorder of pyrimidine metabolism (11)

Sub-types of Mitochondrial neurogastrointestinal encephalomyopathy

Mitochondrial DNA depletion syndrome 1 0 trials
Mitochondrial DNA depletion syndrome 20 (mngie type) 0 trials
Mitochondrial DNA depletion syndrome 4b 0 trials
Mitochondrial DNA depletion syndrome 8a 0 trials

Including sub-types (26) Tagged with Mitochondrial neurogastrointestinal encephalomyopathy (4)

Trials to join now! 15 Not yet recruiting 1 Not yet finished but already full! 5 Completed 3 Terminated 2

New DNA test could end years of uncertainty for mitochondrial disease patients

Diagnosis Not yet recruiting

This pilot study aims to develop a new digital PCR technique to more accurately diagnose mitochondrial diseases. Researchers will test the method on blood, urine, saliva, and muscle fiber samples from 4 patients. If validated, the technique could be faster and cheaper than curren…

Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis

Last updated Jun 27, 2026 12:04 UTC

Mitochondrial neurogastrointestinal encephalomyopathy

Where it sits in the disease tree

New DNA test could end years of uncertainty for mitochondrial disease patients